{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T20:28:34Z","timestamp":1784147314218,"version":"3.55.0"},"reference-count":44,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,9,22]],"date-time":"2021-09-22T00:00:00Z","timestamp":1632268800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100006453","name":"Taisho Toyama Pharmaceutical Co Ltd","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006453","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","diabetesresearchclinicalpractice.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Diabetes Research and Clinical Practice"],"published-print":{"date-parts":[[2021,10]]},"DOI":"10.1016\/j.diabres.2021.109069","type":"journal-article","created":{"date-parts":[[2021,9,23]],"date-time":"2021-09-23T02:24:08Z","timestamp":1632363848000},"page":"109069","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["Lowering of blood pressure and pulse rate by switching from DPP-4 inhibitor to luseogliflozin in patients with type 2 diabetes complicated with hypertension: A multicenter, prospective, randomized, open-label, parallel-group comparison trial (LUNA study)"],"prefix":"10.1016","volume":"180","author":[{"given":"Reina","family":"Hashimoto-Kameda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyu Yong","family":"Cho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Nomoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akinobu","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuno","family":"Omori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"So","family":"Nagai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sachiko","family":"Edagawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinichiro","family":"Kawata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Takeuchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiraku","family":"Kameda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshio","family":"Kurihara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shin","family":"Aoki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsuya","family":"Atsumi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideaki","family":"Miyoshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.diabres.2021.109069_b0005","doi-asserted-by":"crossref","unstructured":"Emerging Risk Factors Collaboration; Sarwar N, Gao P, Kondapally Seshasai SR, et al. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. Lancet. 2010; 375: 2215-22.","DOI":"10.1016\/S0140-6736(10)60484-9"},{"issue":"5","key":"10.1016\/j.diabres.2021.109069_b0010","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1056\/NEJMoa021778","article-title":"Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes","volume":"348","author":"G\u00e6de","year":"2003","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.diabres.2021.109069_b0015","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1016\/S2213-8587(17)30327-3","article-title":"J-DOIT3 Study Group. Effect of an intensified multifactorial intervention on cardiovascular outcomes and mortality in type 2 diabetes (J-DOIT3): an open-label, randomised controlled trial","volume":"5","author":"Ueki","year":"2017","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.diabres.2021.109069_b0020","doi-asserted-by":"crossref","first-page":"327","DOI":"10.2147\/DMSO.S51325","article-title":"Prevalence of hypertension and obesity in patients with type 2 diabetes mellitus in observational studies: a systematic literature review","volume":"6","author":"Colosia","year":"2013","journal-title":"Diabetes Metab Syndr Obes"},{"issue":"9349","key":"10.1016\/j.diabres.2021.109069_b0025","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1016\/S0140-6736(02)11911-8","article-title":"Prospective Studies Collaboration. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies","volume":"360","author":"Lewington","year":"2002","journal-title":"Lancet"},{"issue":"9","key":"10.1016\/j.diabres.2021.109069_b0030","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1038\/s41440-019-0284-9","article-title":"The Japanese society of hypertension guidelines for the management of hypertension (JSH 2019)","volume":"42","author":"Umemura","year":"2019","journal-title":"Hypertens Res"},{"key":"10.1016\/j.diabres.2021.109069_b0035","doi-asserted-by":"crossref","unstructured":"Astrup AS, Nielsen FS, Rossing P, et al. Predictors of mortality in patients with type 2 diabetes with or without diabetic nephropathy: a follow-up study. J Hypertens 2007; 25: 2479\u201385.","DOI":"10.1097\/HJH.0b013e3282f06428"},{"key":"10.1016\/j.diabres.2021.109069_b0040","doi-asserted-by":"crossref","unstructured":"Bouhanick B, Bongard V, Amar J, et al. Prognostic value of nocturnal blood pressure and reverse-dipping status on the occurrence of cardiovascular events in hypertensive diabetic patients. Diabetes Metab. 2008; 34: 560\u20137.","DOI":"10.1016\/j.diabet.2008.05.005"},{"issue":"6","key":"10.1016\/j.diabres.2021.109069_b0045","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1161\/HYPERTENSIONAHA.113.02148","article-title":"Ambulatory blood pressure measurement what is the international consensus?","volume":"62","author":"O\u2019Brien","year":"2013","journal-title":"Hypertension"},{"issue":"1","key":"10.1016\/j.diabres.2021.109069_b0050","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1161\/HYPERTENSIONAHA.109.133900","article-title":"Predictive role of the nighttime blood pressure","volume":"57","author":"Hansen","year":"2011","journal-title":"Hypertension"},{"key":"10.1016\/j.diabres.2021.109069_b0055","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1097\/HJH.0000000000001194","article-title":"Masked tachycardia. A predictor of adverse outcome in hypertension","volume":"35","author":"Palatini","year":"2017","journal-title":"J Hypertens"},{"key":"10.1016\/j.diabres.2021.109069_b0060","first-page":"313","article-title":"Clinical potential of sodium-glucose cotransporter 2 inhibitors in the management of type 2 diabetes","volume":"5","author":"Kim","year":"2012","journal-title":"Diabetes Metab Syndr Obes: Targets and Therapy"},{"issue":"22","key":"10.1016\/j.diabres.2021.109069_b0065","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"EMPA-REG OUTCOME investigators: empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.diabres.2021.109069_b0070","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1056\/NEJMoa1611925","article-title":"CANVAS program collaborative group: canagliflozin and cardiovascular and renal events in type 2 diabetes","volume":"377","author":"Neal","year":"2017","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.diabres.2021.109069_b0075","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1056\/NEJMoa1812389","article-title":"Dapagliflozin and cardiovascular outcomes in type 2 diabetes","volume":"380","author":"Wiviott","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.diabres.2021.109069_b0080","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1161\/CIRCULATIONAHA.118.037076","article-title":"24-Hour blood pressure-lowering effect of an SGLT-2 inhibitor in patients with diabetes and uncontrolled nocturnal hypertension: results from the randomized, placebo-controlled SACRA study","volume":"139","author":"Kario","year":"2018","journal-title":"Circulation"},{"issue":"3","key":"10.1016\/j.diabres.2021.109069_b0085","doi-asserted-by":"crossref","first-page":"455","DOI":"10.2337\/dc15-2145","volume":"39","author":"Mita","year":"2016","journal-title":"Diabetes Care"},{"key":"10.1016\/j.diabres.2021.109069_b0090","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1097\/HJH.0000000000000782","article-title":"Effect of dipeptidyl peptidase-4 inhibitors on blood pressure in patients with type2 diabetes: A systematic review and meta-analysis","volume":"34","author":"Zhang","year":"2016","journal-title":"J Hypertens"},{"issue":"14","key":"10.1016\/j.diabres.2021.109069_b0095","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1056\/NEJMoa1307684","article-title":"SAVOR-TIMI 53 Steering Committee and Investigators. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus","volume":"369","author":"Scirica","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.diabres.2021.109069_b0100","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1001\/jama.2018.18269","article-title":"CARMELINA investigators","volume":"321","author":"Rosenstock","year":"2019","journal-title":"JAMA"},{"issue":"2","key":"10.1016\/j.diabres.2021.109069_b0105","doi-asserted-by":"crossref","first-page":"e034883","DOI":"10.1136\/bmjopen-2019-034883","article-title":"Effects of switching from a dipeptidyl peptidase-4 inhibitor to luseogliflozin on nocturnal blood pressure in patients with type 2 diabetes: protocol for a multicentre, prospective, randomised, open-label, blinded endpoint parallel-group comparison study","volume":"10","author":"Kameda","year":"2020","journal-title":"BMJ Open"},{"issue":"2","key":"10.1016\/j.diabres.2021.109069_b0110","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1111\/jdi.12913","article-title":"Should sulfonylurea be discontinued or maintained at the lowest dose when starting ipragliflozin? A multicenter observational study in Japanese patients with type 2 diabetes","volume":"10","author":"Takahashi","year":"2019","journal-title":"J Diabetes Investig"},{"issue":"8607","key":"10.1016\/j.diabres.2021.109069_b0115","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/S0140-6736(88)92867-X","article-title":"Dippers and non-dippers","volume":"332","author":"O'Brien","year":"1988","journal-title":"Lancet"},{"key":"10.1016\/j.diabres.2021.109069_b0120","first-page":"S354","article-title":"Analysis of the effect of luseogliflozin on patients with type 2 diabetes and hypertension using ambulatory blood pressure monitoring","volume":"60","author":"Shirabe","year":"2017","journal-title":"J Japan Diabetes Soc"},{"issue":"5","key":"10.1016\/j.diabres.2021.109069_b0125","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.117.005686","article-title":"Effects of sodium-glucose cotransporter 2 inhibitors on 24-hour ambulatory blood pressure: a systematic review and meta-analysis","volume":"6","author":"Baker","year":"2017","journal-title":"J Am Heart Assoc"},{"issue":"3","key":"10.1016\/j.diabres.2021.109069_b0130","doi-asserted-by":"crossref","first-page":"420","DOI":"10.2337\/dc14-1096","article-title":"Empagliflozin reduces blood pressure in patients with type 2 diabetes and hypertension","volume":"38","author":"Tikkanen","year":"2015","journal-title":"Diabetes Care"},{"issue":"11","key":"10.1016\/j.diabres.2021.109069_b0135","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.1111\/dom.12962","article-title":"Impact of empagliflozin on blood pressure in dipper and non-dipper patients with type 2 diabetes mellitus and hypertension","volume":"19","author":"Chilton","year":"2017","journal-title":"Diabetes Obes Metab"},{"issue":"3","key":"10.1016\/j.diabres.2021.109069_b0140","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.pcad.2020.04.003","article-title":"Control of 24-hour blood pressure with SGLT2 inhibitors to prevent cardiovascular disease","volume":"63","author":"Kario","year":"2020","journal-title":"Prog Cardiovasc Dis"},{"issue":"8","key":"10.1016\/j.diabres.2021.109069_b0145","doi-asserted-by":"crossref","first-page":"707","DOI":"10.2337\/diacare.14.8.707","article-title":"Circadian rhythm of blood pressure in normotensive NIDDM subjects. Its relationship to microvascular complications","volume":"14","author":"Nakano","year":"1991","journal-title":"Diabetes Care"},{"key":"10.1016\/j.diabres.2021.109069_b0150","first-page":"11","article-title":"Renal, metabolic and cardiovascular considerations of SGLT2 inhibition","volume":"13","author":"DeFronzo","year":"2017","journal-title":"Nephrology"},{"issue":"3","key":"10.1016\/j.diabres.2021.109069_b0155","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1111\/dom.13557","volume":"21","author":"Cho","year":"2019","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.diabres.2021.109069_b0160","first-page":"541","article-title":"Effect of phlorizin on SGLT2 expression in the kidney of diabetic rats","volume":"23","author":"Osorio","year":"2010","journal-title":"J Nephrol"},{"issue":"1","key":"10.1016\/j.diabres.2021.109069_b0165","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0272-6386(99)70254-4","article-title":"Circadian rhythm of natriuresis is disturbed in nondipper type of essential hypertension","volume":"33","author":"Fujii","year":"1999","journal-title":"Am J Kidney Dis"},{"issue":"1","key":"10.1016\/j.diabres.2021.109069_b0170","doi-asserted-by":"crossref","DOI":"10.1186\/s12872-019-1186-0","article-title":"Blood pressure predictors of stroke in rural Chinese dwellers with hypertension: a large-scale prospective cohort study","volume":"19","author":"Zheng","year":"2019","journal-title":"BMC Cardiovasc Disord"},{"key":"10.1016\/j.diabres.2021.109069_b0175","doi-asserted-by":"crossref","unstructured":"Okada K, Iso H, Cui R, et al. Pulse pressure is an independent risk factor for stroke among middle-aged Japanese with normal systolic blood pressure: the JPHC study. J Hypertens. 2011; 29: 319-24.","DOI":"10.1097\/HJH.0b013e32834143d9"},{"key":"10.1016\/j.diabres.2021.109069_b0180","doi-asserted-by":"crossref","unstructured":"Buda VA, Ciobanu DM, Roman G. Pulse pressure is more relevant than systolic and diastolic blood pressure in patients with type 2 diabetes and cardiovascular disease. Clujul Med. 2018; 91: 408-13.","DOI":"10.15386\/cjmed-972"},{"issue":"1","key":"10.1016\/j.diabres.2021.109069_b0185","doi-asserted-by":"crossref","DOI":"10.1186\/s12933-019-0912-3","volume":"18","author":"Kinguchi","year":"2019","journal-title":"Cardiovasc Diabetol"},{"issue":"2","key":"10.1016\/j.diabres.2021.109069_b0190","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1161\/HYPERTENSIONAHA.109.144808","article-title":"Resting heart rate pattern during follow-up and mortality in hypertensive patients","volume":"55","author":"Paul","year":"2010","journal-title":"Hypertension"},{"issue":"12","key":"10.1016\/j.diabres.2021.109069_b0195","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1111\/dom.12572","article-title":"Effects of empagliflozin on blood pressure and markers of arterial stiffness and vascular resistance in patients with type 2 diabetes","volume":"17","author":"Chilton","year":"2015","journal-title":"Diabetes Obes Metab"},{"issue":"7","key":"10.1016\/j.diabres.2021.109069_b0200","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1007\/s00125-020-05145-0","article-title":"Empagliflozin modulates renal sympathetic and heart rate baroreflexes in a rabbit model of diabetes","volume":"63","author":"Gueguen","year":"2020","journal-title":"Diabetologia"},{"issue":"1","key":"10.1016\/j.diabres.2021.109069_b0205","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.tem.2013.09.002","article-title":"Ketone bodies as signaling metabolites","volume":"25","author":"Newman","year":"2014","journal-title":"Trends Endocrinol Metab"},{"issue":"1","key":"10.1016\/j.diabres.2021.109069_b0210","doi-asserted-by":"crossref","first-page":"117","DOI":"10.2337\/dc16-1580","article-title":"Effects of liraglutide on heart rate and heart rate variability: a randomized, double-blind, placebo-controlled crossover study","volume":"40","author":"Kumarathurai","year":"2017","journal-title":"Diabetes Care"},{"key":"10.1016\/j.diabres.2021.109069_b0215","doi-asserted-by":"crossref","unstructured":"Pyke C, Heller RS, Kirk RK, et al. GLP-1 receptor localization in monkey and human tissue: novel distribution revealed with extensively validated monoclonal antibody. Endocrinology. 2014; 155(4): 1280-90.","DOI":"10.1210\/en.2013-1934"},{"key":"10.1016\/j.diabres.2021.109069_b0220","doi-asserted-by":"crossref","unstructured":"Qiong W, Changchang L, Yanfang G, et al. Environmental ambient temperature and blood pressure in adults: A systematic review and meta-analysis. Sci Total Environ 2016; 575: 276-86.","DOI":"10.1016\/j.scitotenv.2016.10.019"}],"container-title":["Diabetes Research and Clinical Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168822721004289?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168822721004289?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T19:20:44Z","timestamp":1759173644000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168822721004289"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10]]},"references-count":44,"alternative-id":["S0168822721004289"],"URL":"https:\/\/doi.org\/10.1016\/j.diabres.2021.109069","relation":{},"ISSN":["0168-8227"],"issn-type":[{"value":"0168-8227","type":"print"}],"subject":[],"published":{"date-parts":[[2021,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Lowering of blood pressure and pulse rate by switching from DPP-4 inhibitor to luseogliflozin in patients with type 2 diabetes complicated with hypertension: A multicenter, prospective, randomized, open-label, parallel-group comparison trial (LUNA study)","name":"articletitle","label":"Article Title"},{"value":"Diabetes Research and Clinical Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.diabres.2021.109069","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"109069"}}